Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.

Two clinical trials that altered vasopressin signaling report improved social functions in people with autism spectrum disorder, but researchers caution against overinterpreting the results.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Breast cancer researcher and oncologist Nancy Davidson discusses what we’ve learned from the first wave of epigenetic trials for breast cancer, and what challenges lie ahead before such therapies reach the clinic.

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

Gottlieb will step down after two years at the helm of the US Food and Drug Administration to spend more time with his family.

In an era of instant communication, we must be careful how word of new and untested treatments is shared.

Plasmodium falciparum has shown an ability to evade everything we throw at it, most recently artemisinin-based combination therapies, today’s front-line treatment.